Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study
Cargando...
Archivos
Fecha
2019
Título de la revista
Publicado en
Lung cancer, 0169-5002, Vol 130, 2019, pag 67-75
Publicado por
Elsevier
ISSN de la revista
Título del volumen
Resumen
Descripción
Abstract
Objectives
Evidence is rapidly accumulating for the use of radical consolidative treatment (RCT) for patients with oligometastatic non-small cell lung cancer (NSCLC). Nonetheless, published studies have several limitations, including a selection of patients whose favorable characteristics might dictate therapeutic success, as well as scarce prospective data regarding overall survival (OS). The objective of this study was to determine whether RCT increases OS in patients with oligometastatic NSCLC.
Materials and methods
In this prospective, single-arm phase II study, we sought to evaluate the efficacy of RCT in patients with oligometastatic NSCLC in terms of OS. Patients with pathologically confirmed stage IV NSCLC who presented ≤5 synchronous, any-site metastases (including central nervous system [CNS] metastases), as assessed by PET-CT, were included. All patients received four initial cycles of systemic treatment. Following, those with stable disease/partial response received RCT to the primary site and metastases. The response to RCT was evaluated with PET-CT. The primary end-point was OS. Secondary end-points included progression-free survival (PFS) and best response by PET-CT. The study is registered in clinicaltrials.gov (NCT02805530).
Results
Thirty-seven patients were included in the analysis. The mean age was 55.8 years (range: 33–75 years). At diagnosis, 43.2% of patients presented with CNS metastases. Following RCT, 19 (51.4%) patients achieved a complete-response (CR) by PET-CT, while 18 (48.6%) had a non-complete response (NON-CR). The median OS was nonreached (NR) and was positively affected by CR on PET-CT (NR vs. 27.4 [95% CI: 16.4–38.3]; p = 0.011). The median PFS was 23.5 months (95% CI: 13.6–33.3) and was positively affected by CR on PET-CT (NR vs. 14.3 [95% CI: 11.7–16.9]; p < 0.001; HR: 0.19 [0.07-0.52]; p=0.001).
Conclusion
Patients with oligometastatic NSCLC who undergo RCT have a high response rate and favorable OS. Patients with a CR by PET-CT have significantly longer OS, rendering this an important potential prognostic marker.
Palabras clave
Keywords
NSCLC, Oligometastatic, Survival, Radical consolidative therapy, Radiotherapy, Surgery
Temáticas
Radioterapia